These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20153398)

  • 21. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 22. [Dopamine dysregulation syndrome in a patient with Parkinson's disease; a case report].
    Hol WM; van der Zwaard R; Hovestadt A; van Megen HJ
    Tijdschr Psychiatr; 2010; 52(4):259-63. PubMed ID: 20503167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
    Gómez-Esteban JC; Zarranz JJ; Lezcano E; Velasco F; Ciordia R; Rouco I; Losada J; Bilbao I
    Mov Disord; 2006 Jul; 21(7):983-8. PubMed ID: 16602112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?].
    Catalan-Alonso MJ; Del Val J
    Rev Neurol; 2001 Jun 1-15; 32(11):1085-7. PubMed ID: 11562835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 27. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R; Aharon-Peretz J; Tsitrinbaum Z
    Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 30. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paraphilia and other disturbed behavior associated with dopamimetic treatment for Parkinson's disease.
    Nielssen OB; Cook RJ; Joffe R; Meagher LJ; Silberstein P
    Mov Disord; 2009 May; 24(7):1091-2. PubMed ID: 19260105
    [No Abstract]   [Full Text] [Related]  

  • 32. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.
    Fernandez HH; Durso R
    Mov Disord; 1998 May; 13(3):597-8. PubMed ID: 9613761
    [No Abstract]   [Full Text] [Related]  

  • 33. Sleep disorders in Parkinson's disease.
    Larsen JP
    Adv Neurol; 2003; 91():329-34. PubMed ID: 12442690
    [No Abstract]   [Full Text] [Related]  

  • 34. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic psychosis in advanced Parkinson's disease.
    Fischer P; Danielczyk W; Simanyi M; Streifler MB
    Adv Neurol; 1990; 53():391-7. PubMed ID: 2122647
    [No Abstract]   [Full Text] [Related]  

  • 36. "Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.
    Růžička E; Zárubová K; Nutt JG; Bloem BR
    Mov Disord; 2011 Aug; 26(9):1782-4. PubMed ID: 21495073
    [No Abstract]   [Full Text] [Related]  

  • 37. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 38. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
    Goetz CG
    Exp Neurol; 1997 Mar; 144(1):17-20. PubMed ID: 9126145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs can trigger pathological gambling.
    Prescrire Int; 2002 Feb; 11(57):16. PubMed ID: 11985369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.